Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR)’s stock price has plunge by -2.15relation to previous closing price of 20.45. Nevertheless, the company has seen a -6.80% plunge in its stock price over the last five trading sessions. investopedia.com reported 2024-09-03 that Shares of Arrowhead Pharmaceuticals (ARWR) gained Tuesday after the biotech firm announced positive results in a late-stage study of its experimental treatment for a rare metabolic disorder, and said it plans to request regulatory approval to market it.
Is It Worth Investing in Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) Right Now?
The stock has a 36-month beta value of 0.98. Opinions on the stock are mixed, with 0 analysts rating it as a “buy,” 1 as “overweight,” 3 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ARWR is 118.50M, and at present, short sellers hold a 7.30% of that float. On September 18, 2024, the average trading volume of ARWR was 1.02M shares.
ARWR’s Market Performance
ARWR stock saw a decrease of -6.80% in the past week, with a monthly decline of -11.85% and a quarterly a decrease of -20.28%. The volatility ratio for the week is 5.71%, and the volatility levels for the last 30 days are 4.96% for Arrowhead Pharmaceuticals Inc. (ARWR). The simple moving average for the last 20 days is -13.10% for ARWR stock, with a simple moving average of -26.64% for the last 200 days.
Analysts’ Opinion of ARWR
Many brokerage firms have already submitted their reports for ARWR stocks, with Goldman repeating the rating for ARWR by listing it as a “Neutral.” The predicted price for ARWR in the upcoming period, according to Goldman is $31 based on the research report published on June 05, 2024 of the current year 2024.
BofA Securities, on the other hand, stated in their research note that they expect to see ARWR reach a price target of $29. The rating they have provided for ARWR stocks is “Buy” according to the report published on December 04th, 2023.
Citigroup gave a rating of “Neutral” to ARWR, setting the target price at $33 in the report published on September 19th of the previous year.
ARWR Trading at -20.54% from the 50-Day Moving Average
After a stumble in the market that brought ARWR to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -49.76% of loss for the given period.
Volatility was left at 4.96%, however, over the last 30 days, the volatility rate increased by 5.71%, as shares sank -14.30% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -21.74% lower at present.
During the last 5 trading sessions, ARWR fell by -6.80%, which changed the moving average for the period of 200-days by -30.95% in comparison to the 20-day moving average, which settled at $22.86. In addition, Arrowhead Pharmaceuticals Inc. saw -34.61% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ARWR starting from Oliver Tracie, who sale 9,394 shares at the price of $25.28 back on Jul 02 ’24. After this action, Oliver Tracie now owns 127,107 shares of Arrowhead Pharmaceuticals Inc., valued at $237,480 using the latest closing price.
Vakiener Victoria, the Director of Arrowhead Pharmaceuticals Inc., sale 1,799 shares at $23.31 during a trade that took place back on May 02 ’24, which means that Vakiener Victoria is holding 30,205 shares at $41,935 based on the most recent closing price.
Stock Fundamentals for ARWR
Current profitability levels for the company are sitting at:
- -27.85 for the present operating margin
- 0.11 for the gross margin
The net margin for Arrowhead Pharmaceuticals Inc. stands at -27.41. The total capital return value is set at -0.7. Equity return is now at value -154.92, with -64.14 for asset returns.
Based on Arrowhead Pharmaceuticals Inc. (ARWR), the company’s capital structure generated 0.51 points at debt to capital in total, while cash flow to debt ratio is standing at -1.03. The debt to equity ratio resting at 1.03. The interest coverage ratio of the stock is -23.83.
Currently, EBITDA for the company is -188.16 million with net debt to EBITDA at -0.74. When we switch over and look at the enterprise to sales, we see a ratio of 146.19. The liquidity ratio also appears to be rather interesting for investors as it stands at 4.65.
Conclusion
To sum up, Arrowhead Pharmaceuticals Inc. (ARWR) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
